Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency: effects on growth hormone secretion and growth.

Hümmelink R, Sippell WG, Benoit KG, Danielson K, Faijerson Y

Acta paediatrica (Oslo, Norway : 1992). Supplement1 Mar 1993Cited by 5 (Europe PMC)

PMID8329828DOI10.1111/j.1651-2227.1993.tb12830.xPepBankPUB-08329828

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanNon-randomized trialPharmacokinetics
In eight short prepubertal children with growth hormone deficiency, intranasal GHRH(1-29)-NH2 on day 1 gave plasma GHRH peaks of 1.2 to 5.4 micrograms/l.
In plain wordsIn children with low growth hormone, GHRH sprayed into the nose reached the blood on day 1, with peaks of 1.2 to 5.4 micrograms/l.
Peptide
Sermorelin
Outcome
Not applicablePlasma GHRH peak after intranasal insufflation (day 1)
Study
n = 8
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Measurements
GHRH plasma peak
1.2 to 5.4 micrograms/l
day 1
Source sentences
Summary
On day 1, GHRH insufflations were followed by distinct GHRH and GH plasma peaks, ranging from 1.2 to 5.4 micrograms/l and from 10 to 85 mIU/l, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982801
02HumanNon-randomized trialEfficacy outcome
In eight short prepubertal children with growth hormone deficiency, intranasal GHRH(1-29)-NH2 on day 1 was followed by plasma GH peaks of 10 to 85 mIU/l.
In plain wordsIn children with low growth hormone, GHRH sprayed into the nose on day 1 was followed by growth hormone peaks of 10 to 85 mIU/l.
Peptide
Sermorelin
Outcome
IncreasePlasma GH peak after intranasal GHRH (day 1)
Study
n = 8
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Measurements
GH plasma peak
10 to 85 mIU/l
day 1
Source sentences
Summary
On day 1, GHRH insufflations were followed by distinct GHRH and GH plasma peaks, ranging from 1.2 to 5.4 micrograms/l and from 10 to 85 mIU/l, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982802
03HumanNon-randomized trialPharmacokinetics
In children with growth hormone deficiency, peak amplitudes after intranasal GHRH(1-29)-NH2 were variably reduced after 6 weeks in most patients and further reduced at 6 months.
In plain wordsIn children with low growth hormone, blood peaks after nasal GHRH shrank in most children by 6 weeks, and more by 6 months.
Peptide
Sermorelin
Outcome
DecreasePlasma peak amplitudes after repeated intranasal dosing
Study
n = 8
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Peak amplitudes were variably reduced after 6 weeks in most patients, and further reduced at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982803
04HumanNon-randomized trialSafety outcome
In eight children treated with intranasal GHRH(1-29)-NH2, GHRH antibodies, initially negative, were positive in three patients after 6 weeks.
In plain wordsIn children given nasal GHRH, three of eight made antibodies against GHRH within 6 weeks.
Peptide
Sermorelin
Outcome
IncreaseGHRH antibody formation
Study
n = 8
Outcome group
Adverse events · Immune and inflammation
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
GHRH antibodies (initially negative) were positive in three patients after 6 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982804
05HumanNon-randomized trialEfficacy outcome
In children with growth hormone deficiency, the mean knemometric growth rate rose from 0.24 to 0.48 mm/week after 6 weeks of intranasal GHRH(1-29)-NH2 (p = 0.03).
In plain wordsIn children with low growth hormone, the short-term growth rate measured by knemometry doubled after 6 weeks of nasal GHRH.
Peptide
Sermorelin
Outcome
IncreaseKnemometric growth rate at 6 weeks
Study
n = 8
Outcome group
Linear growth · Endocrine and hormones
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Measurements
Knemometric growth rate
0.24 mm/week
baseline
Knemometric growth rate
0.48 mm/week
week 6
Source sentences
Summary
The mean knemometric growth rate rose from 0.24 to 0.48 mm/week after 6 weeks of treatment (p = 0.03)
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982805
06HumanNon-randomized trialEfficacy outcome
In children with growth hormone deficiency, the rise in knemometric growth rate under intranasal GHRH(1-29)-NH2 was followed by a rapid decline.
In plain wordsIn children with low growth hormone, the early rise in short-term growth rate with nasal GHRH did not last and fell quickly.
Peptide
Sermorelin
Outcome
DecreaseKnemometric growth rate after week 6
Study
n = 8
Outcome group
Linear growth · Endocrine and hormones
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
and then rapidly declined; the mean 6-month stadiometric height velocity did not increase.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982806
07HumanNon-randomized trialEfficacy outcome
In children with growth hormone deficiency, the mean 6-month stadiometric height velocity did not increase with intranasal GHRH(1-29)-NH2.
In plain wordsIn children with low growth hormone, 6 months of nasal GHRH did not raise average height growth rate.
Peptide
Sermorelin
Outcome
No significant change6-month stadiometric height velocity
Study
n = 8
Outcome group
Linear growth · Endocrine and hormones
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
the mean 6-month stadiometric height velocity did not increase.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982807
08HumanNon-randomized trialSafety outcome
In eight children given intranasal GHRH(1-29)-NH2, most of the patients other than the one with good local tolerance reported sneezing immediately after insufflation.
In plain wordsIn children given nasal GHRH, most sneezed right after the spray.
Peptide
Sermorelin
Outcome
Not applicableSneezing after insufflation
Study
n = 8
Outcome group
Adverse events · Respiratory
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Local tolerance was good in one patient; most others reported sneezing immediately after insufflation, rhinorrhoea and mild mucosal burning.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982808
09HumanNon-randomized trialSafety outcome
In eight children given intranasal GHRH(1-29)-NH2, most of the patients other than the one with good local tolerance reported rhinorrhoea.
In plain wordsIn children given nasal GHRH, most had a runny nose.
Peptide
Sermorelin
Outcome
Not applicableRhinorrhoea after insufflation
Study
n = 8
Outcome group
Adverse events · Respiratory
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Local tolerance was good in one patient; most others reported sneezing immediately after insufflation, rhinorrhoea and mild mucosal burning.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982809
10HumanNon-randomized trialSafety outcome
In eight children given intranasal GHRH(1-29)-NH2, most of the patients other than the one with good local tolerance reported mild mucosal burning.
In plain wordsIn children given nasal GHRH, most felt mild burning in the nose.
Peptide
Sermorelin
Outcome
Not applicableMild mucosal burning after insufflation
Study
n = 8
Outcome group
Adverse events · Respiratory
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Local tolerance was good in one patient; most others reported sneezing immediately after insufflation, rhinorrhoea and mild mucosal burning.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982810
11HumanNon-randomized trialSafety outcome
In eight children given intranasal GHRH(1-29)-NH2, local tolerance was good in only one patient.
In plain wordsIn children given nasal GHRH, only one child tolerated the spray well in the nose.
Peptide
Sermorelin
Outcome
Not applicableLocal tolerance
Study
n = 8
Outcome group
Adverse events · Respiratory
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Local tolerance was good in one patient
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982811
12HumanNon-randomized trialSafety outcome
In eight children given intranasal GHRH(1-29)-NH2, treatment was discontinued in two patients after 6 and 12 weeks.
In plain wordsIn children given nasal GHRH, two stopped treatment, after 6 and 12 weeks.
Peptide
Sermorelin
Outcome
Not applicableTreatment discontinuation
Study
n = 8
Outcome group
Adverse events · Whole body
Studied dose
50 micrograms/kg three times per day · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
Treatment was discontinued in two patients after 6 and 12 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The growth-promoting potential of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in a new formulation for intranasal use was examined in a 6-month pilot study of eight short prepubertal children.
Summary · context
GHRH, 50 micrograms/kg, was insufflated intranasally three times per day over 6 months.
Report a problemFND-0832982812

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.